Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 2/20 | 0.48 |
| ▸ | RARB | P10826 | 2/20 | 0.48 |
| ▸ | RARG | P13631 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19196100 | 0.86 | RARA (0.46) | RARARARBRARGSMN1; SMN2ALOX5 | |
| SCHEMBL4889254 | 0.84 | RARA (0.39) | RARARARBRARGSMN1; SMN2ALOX5 | |
| SCHEMBL5544025 | 0.75 | HRH3 (0.42) | RARARARBRARGSMN1; SMN2ALOX5 | |
| SCHEMBL10590822 | 0.75 | RARA (0.50) | RARARARBRARGSMN1; SMN2ALOX5 | |
| SCHEMBL10590816 | 0.75 | RARA (0.50) | RARARARBRARGSMN1; SMN2ALOX5 | |
| SCHEMBL27362775 | 0.75 | RARA (0.50) | RARARARBRARGSMN1; SMN2ALOX5 | |
| SCHEMBL10590829 | 0.75 | RARA (0.50) | RARARARBRARGSMN1; SMN2ALOX5 | |
| SCHEMBL9630548 | 0.74 | ALOX5 (0.62) | ALOX5 | |
| SCHEMBL3995172 | 0.74 | RARA (0.60) | RARARARBRARGSMN1; SMN2ALOX5 | |
| SCHEMBL427731 | 0.74 | SMN1; SMN2 (0.59) | RARARARBRARGSMN1; SMN2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579479-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| EP-1218361-B1 | OXA- AND THIAZOLE DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1939188-A1 | Oxa-and thiazole derivatives useful as antidiabetic and antiobesity agents | Bristol-Myers Squibb Company (US) | 2008-07-02 | — | — | EP | disclosed |
| US-7241780-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOLS-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
| US-7084162-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-01 | — | — | US | disclosed |
| US-7053106-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1589006-A1 | Oxa- and thiazole derivatives useful as antidiabetics and antidiobesity agents | Bristol-Myers Squibb Company (US) | 2005-10-26 | — | — | EP | disclosed |
| US-6919358-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| US-20050119311-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T (US) | 2005-06-02 | — | — | US | disclosed |
| US-20040171644-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T (US) | 2004-09-02 | — | — | US | disclosed |
| US-20040147560-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2004-07-29 | — | — | US | disclosed |
| US-6727271-B2 | OXAZOLE OR THIAZOLE DERIVATIVES; ANTILIPEMIC AGENTS, HYPOTENSIVES, ANTINEOPLASTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-27 | — | — | US | disclosed |
| US-6653314-B2 | Modulate blood glucose levels, triglyceride levels, insulin levels and non-esterified fatty acid levels | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-25 | — | — | US | disclosed |
| US-20030096846-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T (US) | 2003-05-22 | — | — | US | disclosed |
| US-20030087935-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T (US) | 2003-05-08 | — | — | US | disclosed |
| US-20030069275-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T (US) | 2003-04-10 | — | — | US | disclosed |
| EP-1218361-A1 | OXA- AND THIAZOLE DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-07-03 | — | — | EP | disclosed |
| US-6414002-B1 | ANTILIPEMIC AGENTS; ANTICANCER, ANTITUMOR AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-02 | — | — | US | disclosed |
| WO-2001021602-A1 | OXA- AND THIAZOLE DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069275-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, PNLIP | RARA 215/4885RARB 606/4885RARG 447/4885 |
| US-20040147560-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, PNLIP | RARA 207/4885RARB 565/4885RARG 451/4885 |
| US-20030096846-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, PNLIP | RARA 215/4885RARB 606/4885RARG 447/4885 |
| US-20030087935-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, PNLIP | RARA 215/4885RARB 606/4885RARG 447/4885 |
| US-20050119311-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, ACACA | RARA 188/4885RARB 401/4885RARG 527/4885 |
| US-20040171644-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, PNLIP | RARA 215/4885RARB 606/4885RARG 447/4885 |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, ACACA | RARA 188/4885RARB 401/4885RARG 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.